Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Novartis
Novartis
Memorial Sloan Kettering Cancer Center
Fuzhou General Hospital
Brigham and Women's Hospital
Eli Lilly and Company
Novartis
AstraZeneca
OHSU Knight Cancer Institute
Dana-Farber Cancer Institute
Alpha Biopharma (Jiangsu) Co., Ltd.
Massachusetts General Hospital
Thomas Jefferson University